Metformin Hydrochloride Nitrosamine Testing Handbook: Selection Logic for NDMA, NDSRI and EP Impurity Reference Standards
Metformin hydrochloride (CAS 1115-70-4) is one of the most widely used oral antidiabetic drugs in the world. In December 2019, the Singapore Health Sciences Authority (HSA) was the first to detect excessive NDMA (N-nitrosodimethylamine, CAS 62-75-9) in three batches of metformin formulations and implemented a recall, which immediately triggered a chain reaction of global regulation — the U.S. FDA has cumulatively recalled over 280 batches of extended-release formulations since 2020 (immediate-release tablets were unaffected), and the CDE issued the "Technical Guidelines for the Study of Nitrosamine Impurities in Chemical Drugs (Trial)" (Notice No. 1 of 2020) in May of the same year.
Metformin Hydrochloride
CAS No.:1115-70-4
After the incident subsided, the regulatory focus quietly shifted: in August 2023, the FDA issued a dedicated NDSRI guideline, explicitly requiring companies to evaluate nitrosamine drug substance-related impurities (NDSRI) produced by nitrosation of the API skeleton. For metformin hydrochloride, NDSRI (N-nitrosometformin-type compounds, guanidine nitrosation products) not only differ structurally from NDMA, but their AI calculation framework and the reference standards used for detection are also completely independent — the general NDMA reference standard cannot substitute.
Key figures: The FDA acceptable intake (AI) for NDMA is 96 ng/day, with a finished product limit of approximately 0.032 ppm (MDD 3000 mg); the conservative default AI for unclassified NDSRI is 26.5 ng/day. Both require their own dedicated reference standards for detection, with LC-MS/MS as the common method of choice.
1. Both Are Nitrosamine Issues, but the Mechanisms for Metformin and Valsartan Are Fundamentally Different
The key to understanding the NDMA risk of metformin lies in recognizing its mechanistic difference from the valsartan incident.
Valsartan (2018): Introduced via Process Solvent
The main cause was manufacturers using DMF (N,N-dimethylformamide) as a synthetic solvent; DMF hydrolyzes/decarbonylates under high-temperature or alkaline conditions to produce DMA, and the residual DMA subsequently reacts with a nitrosating agent in the process (such as sodium nitrite) to form NDMA. NDMA was an unintended byproduct induced by the solvent-using process, not an inherent risk of the valsartan API skeleton itself.
Metformin Hydrochloride: Nitrosation of Endogenous Residual Impurity
DMA is a residual impurity from the metformin synthesis reaction, listed as "Impurity F" in the European Pharmacopoeia (EP) with a specification of no more than 0.05% (NMT 0.05%). DMA itself is non-toxic, but once it contacts a nitrosating agent during formulation processing or storage, the following reaction occurs:
(CH₃)₂NH + nitrosating agent → (CH₃)₂N–N=O (NDMA) + H₂O
In actual systems, the nitrosating agent is not free nitrous acid, but the nitrous acid cation (H₂NO₂⁺) or dinitrogen trioxide (N₂O₃) formed from trace nitrite (NO₂⁻) under acidic conditions.
Three Key Risk Nodes
1. Formulation granulation process (main risk source)
Multiple studies have confirmed that the API itself is not the main source of NDMA in the finished product — NDMA is mainly formed during the formulation production step. Taking fluidized-bed granulation as an example: atmospheric NO₂ in the inlet air undergoes nitrosation with residual DMA in the API at high temperature, and the amount of NDMA formed is positively correlated with the NO₂ concentration, DMA content, reaction temperature, and time.
2. Trace nitrite in excipients
Trace nitrite/nitrate can be detected in commonly used excipients and can act as nitrosating agent donors. Reported high-risk excipients include: lactose monohydrate, crospovidone, hypromellose (HPMC), magnesium stearate, and povidone.
3. Continuous accumulation during storage
NDMA can continue to form during formulation storage. Available data show that extended-release tablets (XR) generally have higher detection levels than immediate-release tablets (IR) because of the higher HPMC usage and higher excipient nitrite background. In addition, packaging materials (such as nitrocellulose films) have also been reported as one of the potential nitrosation sources.
2. Regulatory Limits
N-nitrosamines belong to the **"Cohort of Concern"** under ICH M7(R2); the general toxicology threshold (TTC = 1.5 μg/day) does not apply, and the AI must be calculated individually based on a 1/100,000 lifetime cancer risk.
The structure of N-nitrosometformin-type impurities is fundamentally different from NDMA (MW 144~197 vs 74), so the limit framework, method parameters, or reference standards for NDMA cannot be applied. The default limit of 0.009 ppm for unclassified NDSRI is about 3.6 times stricter than the 0.032 ppm for NDMA, placing higher demands on method sensitivity.
3. LC-MS/MS Method Development: Core Parameters and Key Challenges
Why Mass Spectrometry Is Required
NDMA (MW 74) has an extremely low molar absorption coefficient at 254 nm, and the sensitivity of conventional HPLC-UV methods is insufficient for ng/g-level limits. Taking metformin hydrochloride as an example: the finished product limit is 0.032 ppm = 32 ng/g, while the LOQ of conventional UV detection is usually at the μg/g level. LC-MS/MS (triple quadrupole) or GC-MS/MS is the platform accepted by regulatory authorities.
MS Parameters for NDMA and NDMA-d₆
The following ion-pair parameters are from the FDA official LC-MS/MS method (FDA.gov, ranitidine method document) and published literature:
†The MRM parameters for NDMA-d₆ are cited from the water-quality LC-MS/MS literature (Water, Air, Soil Pollut. 2012); the theoretical [M+H]⁺ value is 81.1. In actual drug analysis methods, independent optimization and validation should be performed for the specific instrument platform.
⚠️ DMF Interference Warning: DMF (N,N-dimethylformamide, MW 73) may co-elute with NDMA under certain chromatographic conditions. The 75.1 → 58.1 ion pair is more sensitive to DMF interference; 75.1 → 43.1 is the preferred ion pair for quantification and is relatively less affected by DMF interference (confirmed by SCIEX application reports).
Sample Preparation Strategies
The metformin matrix is highly polar, strongly basic, and has a high API background concentration (hundreds of μg/mL), and treatment approaches differ significantly by dosage form:
Immediate-release tablets (IR): Filter the aqueous extract through a membrane and inject directly; relatively simple with manageable matrix effects.
Extended-release tablets (XR): Avoid extraction with dichloromethane (DCM) — studies show that DCM extraction can cause artificially elevated NDMA signals (artifact formation), because the DCM extract contains both DMA and a nitrosating agent, which can generate NDMA in situ during extraction.
Detection Characteristics of NDSRI (Differences from NDMA)
The molecular weight of N-nitrosometformin-type impurities (NDSRI) (about 144~197) is much larger than that of NDMA (74), and both chromatographic and mass spectrometric behaviors differ:
More polar than NDMA and better retained on RP-C18 columns
MRM ion pairs must be independently developed for the target NDSRI; the 75.1→43.1 parameters for NDMA cannot be applied
ESI positive-ion mode usually gives better response ([M+H]⁺ varies with structure)
4. Metformin Hydrochloride Quality Control: Complete Reference Standard Package
Level 1: Dedicated Nitrosamine Control (Core)
① N-Nitrosometformin (Direct NDSRI Detection)
NDSRI is the current regulatory focus. N-nitrosometformin-type impurities are nitrosation products of the metformin guanidine skeleton with specific structures — there are very few sources worldwide that can stably supply dedicated reference standards, which is the biggest procurement obstacle in method development.
Impurities 1 and 2 have the same molecular formula (C₃H₈N₆O) and are presumed to be positional isomers of the same skeleton; they must be characterized separately during method development and cannot be combined into a single reference standard.
② DMA Precursor Residue Assessment (NDMA Risk Quantification)
DMA is the direct precursor of NDMA; measuring the residual DMA in the API is the quantitative basis for nitrosation risk assessment. The EP specification for Impurity F is NMT 0.05%, and companies must verify it batch by batch.
③ NDMA Finished Product Verification
Detection of NDMA (MW 74, CAS 62-75-9) in the finished product requires the separate procurement of certified reference materials (ISO 17034 CRM) and the NDMA-d₆ isotope-labeled internal standard. CATO does not currently have this product; if needed, we can help connect you to compliant sources. When purchasing, check whether the COA states the assigned content value and expanded uncertainty (k=2).
Level 2: EP Pharmacopoeia Compliance (Completeness of Impurity Profile)
Registration applications must demonstrate that the analytical method can effectively separate and quantify each EP impurity. CATO provides complete coverage of metformin hydrochloride EP Impurities A through F, with multiple salt forms available to meet different method requirements.
Level 3: Synthetic Process Impurity Profile
ICH Q3A requires systematic study of known and unknown impurities present in the API and the establishment of a complete impurity profile. The metformin synthesis route involves various guanidine derivatives, and reference standards must be available for both process development and commercial production stages.
CATO has cataloged more than 24 metformin hydrochloride synthesis-related impurities, covering guanidine dimers, degradation products, photodegradation products, and various salt forms.
Level 4: API and System Suitability
Method development and system suitability testing require an API reference standard as the matrix standard and reference material for chromatographic system evaluation; pharmacokinetic studies require deuterated internal standards.
Note: Metformin-d₆ is the isotope-labeled internal standard for API assay, with a use distinct from the NDMA-d₆ used for nitrosamine detection; the two must not be mixed.
CATO holds CNAS/ANAB dual-accredited ISO 17034 certification, with all products accompanied by COA and a complete traceability chain, meeting the traceability requirements for reference standards in ICH Q2(R1) method validation.
For more metformin product details, please contact CATO